Clinical Trial

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Study acronym: READY-AD
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).
Protocol Amendment History 4 changes
critical Enrollment closed, study ongoing 2026-08-01
notable Trial sites expanded: 56 -> 62 locations 2026-06-06
notable Trial sites expanded: 52 -> 56 locations 2026-05-09
notable Trial sites expanded: 30 -> 52 locations 2026-04-14
Trial Details
NCT Number NCT07230860
Lead Sponsor Janssen Research & Development, LLC
Conditions Dermatitis, Atopic
Enrollment 189 participants
Start Date 2026-01-20
Primary Completion 2026-11-19 (estimated)
Study Completion 2028-02-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-31